13
Views
17
CrossRef citations to date
0
Altmetric
Case Report

Successful Treatment of Pulmonary Mucormycosis in an Allogenic Bone-marrow Transplant Recipient with Combined Medical and Surgical Therapy

, , , , , , , & show all
Pages 767-769 | Published online: 24 Dec 2012

  • Morrison VA, McGlave PB. BMucormycosis in the BMT population. Bone Marrow Transplant 1993; 11: 383–8.
  • Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in haematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–17.
  • Maertens J, Demuynck H, Verbeken EK, Zachee P, Verhoef G, Vandenberghe P, Boogaerts MA. Mucormycosis in allogenic bone marrow transplantation: report of 5 cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24: 307–12.
  • Tedder M, Spratt JA, Anstadt MP, Hedge SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57: 1044–50.
  • Lee FYW, Mossad SB, Adal KA. Pulmonary mucormycosis. Arch Int Med 1999; 159: 1301–9.
  • Bigby TD, Serota ML, Tierney LM, Matthay MA. Clinical spectrum of pulmonary mucormycosis. Chest 1986; 89: 435–9.
  • McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF Jr. Pulmonary mucormycosis: radiological findings in 32 cases. Am J Roentgenol 1997; 168: 1541–8.
  • Ascioglu S, Rex JH, de Paws B, Benett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromized patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
  • Herbrecht R, Denning DW, Patterson TF, Benett JE, Greene RE, Oestmann JW, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer, and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–15.
  • Gome-Lopez A, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomy-cota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chem 2001; 48: 919–21.
  • Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of haematopoietic stem cell transplants. N Engl J Med 2004; 350: 950–2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.